Phospho-PIM1 (Y309) Antibody

What is the specific target of Phospho-PIM1 (Y309) Antibody?

Phospho-PIM1 (Y309) antibodies specifically recognize the phosphorylated tyrosine residue at position 309 of the PIM1 protein. The immunogen used for generating these antibodies is a synthesized peptide derived from human PIM1 around the phosphorylation site of Tyr309 . This specificity is critical for distinguishing the phosphorylated form from non-phosphorylated PIM1. PIM1 (Proviral Integration site for Moloney murine leukemia virus 1) is a serine/threonine-protein kinase belonging to the protein kinase superfamily, with a molecular weight of approximately 35.7 kDa . The antibody exhibits no cross-reactivity with other phosphorylated sites on PIM1 or with unrelated phosphorylated proteins .

What applications are validated for Phospho-PIM1 (Y309) Antibody?

Phospho-PIM1 (Y309) antibodies have been validated for multiple research applications, with established protocols for each method:

These applications enable researchers to detect and quantify phosphorylated PIM1 (Y309) in various experimental contexts, from protein lysates to intact cellular systems .

What species reactivity does Phospho-PIM1 (Y309) Antibody demonstrate?

The Phospho-PIM1 (Y309) antibody demonstrates cross-reactivity with multiple species, making it versatile for comparative studies across model organisms:

This multi-species reactivity is particularly valuable for translational research connecting findings between animal models and human systems .

How should Phospho-PIM1 (Y309) Antibody be stored for optimal performance?

Proper storage conditions are essential for maintaining antibody performance and stability over time:

• Long-term storage: -20°C for up to one year

• Short-term/frequent use: 4°C for up to one month

• Shipping condition: 4°C

• Buffer composition: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide

• Handling recommendation: Avoid repeated freeze-thaw cycles as this may denature the antibody and reduce binding efficacy

For aliquoting upon delivery, divide into single-use volumes before storing at -20°C or -80°C to prevent degradation from multiple freeze-thaw cycles .

How can I validate the specificity of Phospho-PIM1 (Y309) Antibody in my experiments?

Validating antibody specificity is crucial for ensuring reliable experimental results. For Phospho-PIM1 (Y309) antibody, several validation approaches are recommended:

• Blocking peptide competition assay: Perform Western blot analysis with two identical samples, treating one with the phospho-peptide that corresponds to the immunogen. The signal should be blocked or significantly reduced in the peptide-treated sample, as demonstrated in validation studies with HUVEC cells treated with PMA .

• Phosphatase treatment control: Treat one sample with lambda phosphatase before immunoblotting to remove phosphorylation. The signal should disappear or significantly decrease compared to untreated samples.

• Stimulation-dependent phosphorylation: Compare samples from unstimulated cells versus cells treated with known activators of PIM1 phosphorylation (e.g., PMA at 125ng/ml for 30 minutes) .

• Knockout/knockdown controls: Use PIM1 knockout or knockdown samples as negative controls to confirm antibody specificity.

These validation strategies ensure that the observed signals genuinely represent phosphorylated PIM1 (Y309) rather than non-specific binding.

What controls should I include when working with Phospho-PIM1 (Y309) Antibody?

Proper experimental controls are essential for meaningful interpretation of results:

• Positive control: Use cell lysates known to express phosphorylated PIM1 (Y309), such as HUVEC cells treated with PMA (125ng/ml for 30 minutes) .

• Negative controls:

  • Secondary antibody only (no primary antibody) to assess background signal

  • Non-phosphorylated recombinant PIM1 protein to confirm phospho-specificity

  • Competing peptide block to verify epitope specificity

• Loading controls: Include detection of housekeeping proteins (e.g., GAPDH, β-actin) or total PIM1 on separate blots or after stripping and reprobing.

• Cell number normalization: For cell-based ELISAs, use crystal violet staining (absorbance at 595nm) to normalize results to cell number, calculating normalized phosphorylation as OD450/OD595 .

Inclusion of these controls enhances data reliability and facilitates accurate interpretation of experimental outcomes.

How do I optimize cell fixation procedures for cell-based ELISA using Phospho-PIM1 (Y309) Antibody?

Cell fixation is a critical step in cell-based ELISA protocols that affects epitope preservation and antibody accessibility:

• Cell density optimization: Seed cells at 75-90% confluence for adherent cells; density should be optimized based on cell type and growth characteristics .

• Fixation protocol:

  • For adherent cells: Use 4% formaldehyde in PBS

  • For suspension or loosely attached cells: Use 8% formaldehyde in PBS

  • Fixation time: 25-30 minutes at room temperature

  • Seal plates with parafilm during fixation to minimize formaldehyde evaporation

• Surface preparation for suspension cells: Pre-coat plates with 100μl of 10μg/ml poly-L-Lysine for 30 minutes at 37°C, followed by two PBS rinses .

• Post-fixation processing:

  • Rinse cells three times with wash buffer (5 minutes each wash with gentle shaking)

  • Apply quench buffer for 20-25 minutes at room temperature before proceeding to blocking

• Safety considerations: Always wear appropriate personal protective equipment (mask, gloves, safety glasses) when handling formaldehyde due to its volatility and toxicity .

These optimization steps ensure proper preservation of the phosphorylated epitope while maintaining cellular morphology.

What are the recommended dilution factors for different applications?

Using appropriate antibody dilutions is essential for optimal signal-to-noise ratio. For Phospho-PIM1 (Y309) antibody:

These recommendations provide starting points, and each researcher should perform dilution series optimization for their specific experimental conditions, cell types, and detection systems .

How can I distinguish between specific and non-specific binding?

Distinguishing specific from non-specific signals is crucial for accurate data interpretation:

• Peptide competition assay: Compare results with and without pre-incubation with the phospho-peptide immunogen. Specific signals will be significantly reduced with peptide competition, as demonstrated in validation studies with HUVEC cells .

• Molecular weight verification: Confirm that the detected band appears at the expected molecular weight for PIM1 (approximately 35.7 kDa) .

• Signal pattern analysis: Specific phosphorylation signals should change predictably with stimulation or inhibition treatments, while non-specific binding typically remains constant.

• Background reduction strategies:

  • Optimize blocking conditions (duration, buffer composition)

  • Increase wash duration and frequency

  • Adjust antibody concentration to minimize non-specific binding

  • Use highly purified antibody preparations (the Phospho-PIM1 (Y309) antibody is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen)

These approaches collectively enable researchers to confidently identify genuine phospho-PIM1 (Y309) signals.

What factors might affect Phospho-PIM1 (Y309) signal intensity?

Multiple factors can influence signal intensity and should be considered during experimental design and troubleshooting:

• Protein extraction methods: Different lysis buffers and extraction protocols may affect phospho-epitope preservation. Include phosphatase inhibitors to prevent dephosphorylation during sample preparation.

• Sample handling: Prolonged storage or multiple freeze-thaw cycles can decrease phosphorylation levels. Process samples quickly and store at appropriate temperatures.

• Stimulation conditions: Optimize stimulation parameters (concentration, duration, temperature) for maximum phosphorylation. For example, PMA treatment at 125ng/ml for 30 minutes has been validated for inducing PIM1 Y309 phosphorylation in HUVEC cells .

• Cell confluency and passage number: These factors can affect baseline phosphorylation states. Standardize cell culture conditions across experiments.

• Detection system sensitivity: Different visualization methods (chemiluminescence, fluorescence, colorimetric) offer varying sensitivity ranges.

• Antibody quality and storage: Antibody degradation affects performance. Store as recommended (-20°C long-term, 4°C short-term) .

Controlling these variables enhances reproducibility and accurate quantification of phosphorylation levels.

How should I normalize Phospho-PIM1 (Y309) signals in relation to total PIM1 expression?

Proper normalization is essential for meaningful interpretation of phosphorylation changes:

• Total protein normalization: The most accurate approach is normalizing phospho-PIM1 signal to total PIM1 protein levels. This requires:

  • Running duplicate samples or stripped and reprobed membranes

  • Using a validated total PIM1 antibody (non-phospho-specific)

  • Calculating the phospho-PIM1/total PIM1 ratio

• Cell-based ELISA normalization:

  • Use crystal violet cell staining (absorbance at 595nm) to normalize for cell number

  • Calculate normalized phosphorylation as OD450/OD595

  • This method accounts for well-to-well variations in cell number

• Housekeeping protein considerations: While often used, housekeeping proteins may not accurately reflect total PIM1 expression changes. When used, verify that experimental conditions do not alter housekeeping protein expression.

• Technical replicate consistency: Ensure technical replicates show minimal variation before calculating normalized values.

Proper normalization approaches allow for accurate quantification of relative phosphorylation changes independent of total protein expression differences.

What are common pitfalls in interpreting Phospho-PIM1 (Y309) data across different cell types?

Researchers should be aware of several potential pitfalls when comparing phospho-PIM1 data across different experimental systems:

• Basal phosphorylation level variations: Different cell types may exhibit varying baseline phosphorylation states. Always include unstimulated controls for each cell type.

• Cell type-specific signaling contexts: The signaling pathways regulating PIM1 Y309 phosphorylation may differ between cell types, affecting stimulation responses.

• Protein expression level differences: Total PIM1 expression varies across cell types, affecting the maximum possible phosphorylation signal. Normalize to total PIM1 rather than making direct phospho-signal comparisons.

• Antibody sensitivity thresholds: Low PIM1 expression may result in signals below detection threshold in some cell types despite actual phosphorylation.

• Post-translational modification interactions: Other modifications on PIM1 may affect Y309 phosphorylation detection in a cell type-specific manner.

• Fixation efficiency differences: Various cell types may require modified fixation protocols for optimal epitope preservation in cell-based assays .

Awareness of these potential issues enables more accurate cross-cell type comparisons and interpretation.

How can Phospho-PIM1 (Y309) Antibody be utilized in studying cancer signaling pathways?

PIM1 plays significant roles in cancer signaling networks, making phospho-specific antibodies valuable for oncology research:

• Phosphorylation dynamics during oncogenic signaling: Monitor Y309 phosphorylation changes in response to upstream pathway activators or inhibitors to map signaling cascades.

• Therapeutic response monitoring: Evaluate how cancer therapeutics affect PIM1 phosphorylation as a pharmacodynamic biomarker.

• Cell cycle regulation studies: Investigate how PIM1 Y309 phosphorylation levels change throughout the cell cycle in normal versus cancer cells.

• Cancer type profiling: Compare phosphorylation patterns across cancer types and stages to identify potential diagnostic or prognostic indicators.

• Drug resistance mechanisms: Explore whether altered PIM1 phosphorylation contributes to resistance against targeted therapies.

• Functional consequences: Correlate Y309 phosphorylation status with PIM1 kinase activity, substrate specificity, and downstream oncogenic functions.

These applications leverage the phospho-specific nature of the antibody to gain insights into cancer biology and potential therapeutic vulnerabilities.

What are the advantages of using cell-based ELISA versus traditional Western blot?

Both methods have distinct advantages for different research questions:

Cell-based ELISA is particularly advantageous for screening studies, temporal phosphorylation dynamics, and when preserving cellular context is important .

How can I incorporate Phospho-PIM1 (Y309) detection in multiplexed assays?

Multiplexed detection enables simultaneous analysis of multiple phosphorylation sites or proteins:

• Multicolor fluorescent Western blotting:

  • Use differentially labeled secondary antibodies (e.g., red for phospho-PIM1, green for total PIM1)

  • Ensure primary antibodies are from different host species to avoid cross-reactivity

  • Validate that each antibody performs similarly in multiplexed format as in single detection

• Sequential probing strategies:

  • Start with phospho-PIM1 detection

  • Document results thoroughly

  • Strip membrane with validated stripping buffer

  • Reprobe for total PIM1 or related pathway components

  • Verify complete stripping by incubating with secondary antibody only

• Pathway-focused multiplexing:

  • Combine phospho-PIM1 (Y309) detection with antibodies against upstream regulators or downstream targets

  • Create phosphorylation profiles that map entire signaling cascades

  • Correlate phosphorylation patterns with functional outcomes

• Technical considerations:

  • Optimize antibody concentrations individually before combining

  • Confirm absence of spectral overlap in detection channels

  • Include single-antibody controls alongside multiplexed samples

These approaches enhance the information obtained from each experiment while conserving valuable samples.

What is the relationship between PIM1 Y309 phosphorylation and kinase activity?

Understanding the functional significance of Y309 phosphorylation provides crucial context for research findings:

• Structural implications: Y309 phosphorylation may induce conformational changes affecting substrate binding or catalytic activity. Researchers should correlate phosphorylation status with:

  • In vitro kinase activity assays

  • Substrate phosphorylation levels

  • Protein-protein interaction profiles

• Regulatory significance: Y309 phosphorylation may represent:

  • An activating modification enhancing kinase function

  • A regulatory mechanism controlling subcellular localization

  • A marker of specific activation pathways

• Experimental approaches to investigate function:

  • Compare kinase activity in wild-type versus Y309F mutant (phospho-deficient) PIM1

  • Utilize phosphomimetic mutations (Y309D/E) to simulate constitutive phosphorylation

  • Correlate Y309 phosphorylation timing with cellular functions

• Pathway integration: Consider Y309 phosphorylation in relation to other PIM1 modifications and pathway components:

  • Other phosphorylation sites on PIM1

  • Upstream kinases responsible for Y309 phosphorylation

  • Phosphatases regulating the modification

These investigations help establish the biological significance of Y309 phosphorylation beyond merely detecting its presence.